血清糖类抗原125、人附睾上皮分泌蛋白4和卵巢癌风险预测指数联合检测在卵巢癌早期诊断中的临床价值
|
摘要
目的探讨血清糖类抗原125(CA125)、人附睾上皮分泌蛋白4(HE4)和卵巢癌风险预测指数(ROMA)在卵巢癌早期诊断中的临床价值。方法选取我院2017年2月～2018年7月收治的50例卵巢癌患者、50例卵巢良性病变患者和50例健康体检者作为研究对象,采用电化学发光法分别检测三组血清HE4和CA125,并计算其ROMA,评价其单独和联合检测在卵巢癌早期诊断中的临床价值。结果卵巢癌组的HE4、CA125、ROMA明显高于卵巢良性病变组和健康对照组,差异有统计学意义(P<0.05),而良性肿瘤组和健康体检组的HE4、CA125、ROMA比较,差异无统计学意义(P>0.05)。联合检测HE4、CA125及ROMA指数诊断卵巢癌具有明显优势。结论联合检测HE4和CA125以及ROMA指数在卵巢早期诊断中具有重要的临床辅助价值。
Objective To explore the clinical value of serum carbohydrate antigen 125(CA125), human epididymal secretion protein 4(HE4) and ovarian cancer risk prediction index(ROMA) in the early diagnosis of ovarian cancer.Methods A total of 50 cases of ovarian cancer, 50 cases of benign ovarian lesions and 50 cases of healthy physical examination were selected as study objects from February 2017 to July 2018 in our hospital. Serum HE4 and CA125 in the 3 groups were tested by electrochemical luminescence method and their ROMA were calculated for dynamic comparison. The clinical value of single and combined detection in early diagnosis of ovarian cancer was evaluated. Results HE4 and CA125 and ROMA in ovarian cancer group were significantly higher than those in benign ovarian tumor group and healthy control group, and the differences were statistically significant(P <0.05). The differences of HE4,CA125 and ROMA between the benign ovarian tumor group and the healthy control group were not statistically significant(P>0.05). Combined detection of HE4, CA125 and ROMA indec had a significant advantage in diagnosing ovarian cancer. Conclusion Combined detection of HE4 and CA125 and ROMA index has important clinical value in early diagnosis of ovary.
Objective To explore the clinical value of serum carbohydrate antigen 125(CA125), human epididymal secretion protein 4(HE4) and ovarian cancer risk prediction index(ROMA) in the early diagnosis of ovarian cancer.Methods A total of 50 cases of ovarian cancer, 50 cases of benign ovarian lesions and 50 cases of healthy physical examination were selected as study objects from February 2017 to July 2018 in our hospital. Serum HE4 and CA125 in the 3 groups were tested by electrochemical luminescence method and their ROMA were calculated for dynamic comparison. The clinical value of single and combined detection in early diagnosis of ovarian cancer was evaluated. Results HE4 and CA125 and ROMA in ovarian cancer group were significantly higher than those in benign ovarian tumor group and healthy control group, and the differences were statistically significant(P <0.05). The differences of HE4,CA125 and ROMA between the benign ovarian tumor group and the healthy control group were not statistically significant(P>0.05). Combined detection of HE4, CA125 and ROMA indec had a significant advantage in diagnosing ovarian cancer. Conclusion Combined detection of HE4 and CA125 and ROMA index has important clinical value in early diagnosis of ovary.
引文
[1]Guo FJ,Shao YP,Wang YP,et al.MIR-92 stimulates VEGF by inhibiting von Hippel-Lindau gene product in epithelial ovarian cancer[J].J Biol Regul Homeost Agents,2017,31(3):615-624.
[2]Badgwell D,Bast RC,Early detection of ovarian cancer[J].Disease Markers,2017,23(5-6):397-410.
[3]陈燕,林莺莺,郑瑜宏,等.血清HE4_CA125和ROMA指数评估卵巢癌风险性的初步评价[J].中国免疫学杂志,2013,29(2):168-174
[4]白珊珊,何雅军.CA125、CA724联合检测在卵巢癌诊断中的应用[J].国际检验医学杂志,2016,37(5):639.
[5]李蕾,沈铿.卵巢癌肿瘤异质性的研究进展及其临床意义[J].现代妇产科进展,2016,25(4):308-310.
[6]谌文丽,秦丰江,方娟.人附睾分泌蛋白4检测对恶性肿瘤鉴别及病理特征的关系[J].中国热带医学,2016,16(6):605-607.
[7]涂彬彬,吴令英,李宁.血清肿瘤标志物诊断早期卵巢癌的相关研究进展[J].癌症进展,2014,12(4):346-350.
[8]雷震山,高鹏,吴金斌.联合检测血清HE4和CA125对卵巢癌患者的临床诊断价值探讨[J].国际检验医学杂志,2016,37(4):544-546.
[9]黄茂华,王树英,伍克,等.糖类抗原-125与人附睾蛋白4联合检测女性卵巢及子宫疾病的研究[J].检验医学与临床,2015,12(13):1904-1906.
[10]雷震山,高鹏,吴金斌.联合检测血清HE4和CA125对卵巢癌患者的临床诊断价值探讨[J].国际检验医学杂志,2016,37(4):544-546.
[11]Kirchoff C,Habben I,Lvell R,et al.Amajor human epididymis-speciffic cDNA enciders a protein with sequence homology to extracellular proteinase inhibitors[J].Biol Reprod,1991,45(2):350-357.
[12]Kristjansdottir B,Levan K,Partheen K,et al.Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancerr[J].Gynecol Oncol,2013,131(1):52-58.
[13]Montagnana M,Benati M,Danese E.Circulating biomarkers in epi-thelial ovarian cancer diagnosis:from present to future perspective[J].Ann Transl Med,2017,5(13):276.
[14]赵瑞珩.ROC曲线评价血清CA125、CA199和CEA对卵巢癌的诊断价值[J].中国实验诊断学,2015,19(11):1954-1955.
[15]Guo J,Yu J,Song X,et al.Serum CA125,CA199 and CEA combined detection for epithelial ovarian cancer diagnosis:A meta analysis[J].Open Med(Wars),2017,12(6):131-137.
[16]Lee S,Choi S,Lee Y,et al.Role of human epididymis protein4 inhemoresistance and prognosis of epithelial ovarian cancer[J].J Obstet Gynaecol Res,2017,43(1):220-222.
[17]Anastasi E,Capoccia D,Granato T,et al.Assessing the association between 25-OH vitamin D levels and ROMA score in a population of obese women[J].J Biol Regul Homeost Agents,2016,30(4):1165-1171.
[18]董动丽,顾劲松,赵绍杰,等.血清HE4、CA125检测及ROMA模型在卵巢癌诊中的应用价值[J].重庆医学,2017,46(5):577-579.
[19]Terlikowska KM,Dobrzycka B,Witkowska AM,et al.Preop erative HE4,CA125 and ROMA in the differential diagnosis of benignand malignant adnexal masses[J].J Ovarian Res,2016,9(1):43.
[2]Badgwell D,Bast RC,Early detection of ovarian cancer[J].Disease Markers,2017,23(5-6):397-410.
[3]陈燕,林莺莺,郑瑜宏,等.血清HE4_CA125和ROMA指数评估卵巢癌风险性的初步评价[J].中国免疫学杂志,2013,29(2):168-174
[4]白珊珊,何雅军.CA125、CA724联合检测在卵巢癌诊断中的应用[J].国际检验医学杂志,2016,37(5):639.
[5]李蕾,沈铿.卵巢癌肿瘤异质性的研究进展及其临床意义[J].现代妇产科进展,2016,25(4):308-310.
[6]谌文丽,秦丰江,方娟.人附睾分泌蛋白4检测对恶性肿瘤鉴别及病理特征的关系[J].中国热带医学,2016,16(6):605-607.
[7]涂彬彬,吴令英,李宁.血清肿瘤标志物诊断早期卵巢癌的相关研究进展[J].癌症进展,2014,12(4):346-350.
[8]雷震山,高鹏,吴金斌.联合检测血清HE4和CA125对卵巢癌患者的临床诊断价值探讨[J].国际检验医学杂志,2016,37(4):544-546.
[9]黄茂华,王树英,伍克,等.糖类抗原-125与人附睾蛋白4联合检测女性卵巢及子宫疾病的研究[J].检验医学与临床,2015,12(13):1904-1906.
[10]雷震山,高鹏,吴金斌.联合检测血清HE4和CA125对卵巢癌患者的临床诊断价值探讨[J].国际检验医学杂志,2016,37(4):544-546.
[11]Kirchoff C,Habben I,Lvell R,et al.Amajor human epididymis-speciffic cDNA enciders a protein with sequence homology to extracellular proteinase inhibitors[J].Biol Reprod,1991,45(2):350-357.
[12]Kristjansdottir B,Levan K,Partheen K,et al.Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancerr[J].Gynecol Oncol,2013,131(1):52-58.
[13]Montagnana M,Benati M,Danese E.Circulating biomarkers in epi-thelial ovarian cancer diagnosis:from present to future perspective[J].Ann Transl Med,2017,5(13):276.
[14]赵瑞珩.ROC曲线评价血清CA125、CA199和CEA对卵巢癌的诊断价值[J].中国实验诊断学,2015,19(11):1954-1955.
[15]Guo J,Yu J,Song X,et al.Serum CA125,CA199 and CEA combined detection for epithelial ovarian cancer diagnosis:A meta analysis[J].Open Med(Wars),2017,12(6):131-137.
[16]Lee S,Choi S,Lee Y,et al.Role of human epididymis protein4 inhemoresistance and prognosis of epithelial ovarian cancer[J].J Obstet Gynaecol Res,2017,43(1):220-222.
[17]Anastasi E,Capoccia D,Granato T,et al.Assessing the association between 25-OH vitamin D levels and ROMA score in a population of obese women[J].J Biol Regul Homeost Agents,2016,30(4):1165-1171.
[18]董动丽,顾劲松,赵绍杰,等.血清HE4、CA125检测及ROMA模型在卵巢癌诊中的应用价值[J].重庆医学,2017,46(5):577-579.
[19]Terlikowska KM,Dobrzycka B,Witkowska AM,et al.Preop erative HE4,CA125 and ROMA in the differential diagnosis of benignand malignant adnexal masses[J].J Ovarian Res,2016,9(1):43.